CD8A and neoplasm: Given, that CD8+ T‐cells are recognized as key drivers of antitumoral responses, a better understanding of the CD8+ tumor‐infiltrating lymphocyte (TIL) heterogeneity in HPV‐negative patients is needed to improve the treatment for this subgroup of HNSCC.